330 related articles for article (PubMed ID: 23242358)
1. Parkinson disease psychosis: Update.
Friedman JH
Behav Neurol; 2013 Jan; 27(4):469-77. PubMed ID: 23242358
[TBL] [Abstract][Full Text] [Related]
2. Treatment of psychosis in Parkinson's disease: safety considerations.
Fernandez HH; Trieschmann ME; Friedman JH
Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease psychosis 2010: a review article.
Friedman JH
Parkinsonism Relat Disord; 2010 Nov; 16(9):553-60. PubMed ID: 20538500
[TBL] [Abstract][Full Text] [Related]
4. Current Understanding of Psychosis in Parkinson's Disease.
Ojo OO; Fernandez HH
Curr Psychiatry Rep; 2016 Oct; 18(10):97. PubMed ID: 27629356
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions for psychosis in Parkinson's disease patients.
Friedman JH
Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
[TBL] [Abstract][Full Text] [Related]
6. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
Merims D; Balas M; Peretz C; Shabtai H; Giladi N
Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
[TBL] [Abstract][Full Text] [Related]
7. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
Zahodne LB; Fernandez HH
Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
[TBL] [Abstract][Full Text] [Related]
9. Atypical antipsychotic drugs in the treatment of Parkinson's disease.
Friedman JH
J Pharm Pract; 2011 Dec; 24(6):534-40. PubMed ID: 22095576
[TBL] [Abstract][Full Text] [Related]
10. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
Isaacson SH; Citrome L
Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
[TBL] [Abstract][Full Text] [Related]
11. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
Hermanowicz S; Hermanowicz N
Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168
[TBL] [Abstract][Full Text] [Related]
12. Management of psychosis in Parkinson's disease.
D'Souza C; Gupta A; Alldrick MD; Sastry BS
Int J Clin Pract; 2003 May; 57(4):295-300. PubMed ID: 12800461
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease psychosis management: an evidence based, experience informed, pragmatic approach.
Friedman JH
Expert Opin Pharmacother; 2024 Feb; 25(2):149-156. PubMed ID: 38344806
[TBL] [Abstract][Full Text] [Related]
15. Treatment of behavioural symptoms and dementia in Parkinson's disease.
Hanagasi HA; Emre M
Fundam Clin Pharmacol; 2005 Apr; 19(2):133-46. PubMed ID: 15810893
[TBL] [Abstract][Full Text] [Related]
16. Psychosis in nursing home patients with Parkinson's disease.
Kang GA; Bronstein JM
J Am Med Dir Assoc; 2004; 5(3):167-73. PubMed ID: 15115577
[TBL] [Abstract][Full Text] [Related]
17. Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.
Broadstock M; Ballard C; Corbett A
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):779-86. PubMed ID: 25301532
[TBL] [Abstract][Full Text] [Related]
18. Psychotic symptoms in Parkinson's disease: pathophysiology and management.
Bosboom JL; Wolters ECh
Expert Opin Drug Saf; 2004 May; 3(3):209-20. PubMed ID: 15155149
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
[No Abstract] [Full Text] [Related]
20. Management of hallucinations and psychosis in Parkinson's disease.
Eng ML; Welty TE
Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
